A citation-based method for searching scientific literature

Mohammed Eslam, Arun J Sanyal, Jacob George. Gastroenterology 2020
Times Cited: 990







List of co-cited articles
669 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement.
Mohammed Eslam, Philip N Newsome, Shiv K Sarin, Quentin M Anstee, Giovanni Targher, Manuel Romero-Gomez, Shira Zelber-Sagi, Vincent Wai-Sun Wong, Jean-François Dufour, Jörn M Schattenberg,[...]. J Hepatol 2020
43

Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes.
Zobair M Younossi, Aaron B Koenig, Dinan Abdelatif, Yousef Fazel, Linda Henry, Mark Wymer. Hepatology 2016
25

The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases.
Naga Chalasani, Zobair Younossi, Joel E Lavine, Michael Charlton, Kenneth Cusi, Mary Rinella, Stephen A Harrison, Elizabeth M Brunt, Arun J Sanyal. Hepatology 2018
24

Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention.
Zobair Younossi, Quentin M Anstee, Milena Marietti, Timothy Hardy, Linda Henry, Mohammed Eslam, Jacob George, Elisabetta Bugianesi. Nat Rev Gastroenterol Hepatol 2018
24


Design and validation of a histological scoring system for nonalcoholic fatty liver disease.
David E Kleiner, Elizabeth M Brunt, Mark Van Natta, Cynthia Behling, Melissa J Contos, Oscar W Cummings, Linda D Ferrell, Yao-Chang Liu, Michael S Torbenson, Aynur Unalp-Arida,[...]. Hepatology 2005
14

The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease.
Mohammed Eslam, Shiv K Sarin, Vincent Wai-Sun Wong, Jian-Gao Fan, Takumi Kawaguchi, Sang Hoon Ahn, Ming-Hua Zheng, Gamal Shiha, Yusuf Yilmaz, Rino Gani,[...]. Hepatol Int 2020
198
13

MAFLD identifies patients with significant hepatic fibrosis better than NAFLD.
Sakura Yamamura, Mohammed Eslam, Takumi Kawaguchi, Tsubasa Tsutsumi, Dan Nakano, Shinobu Yoshinaga, Hirokazu Takahashi, Keizo Anzai, Jacob George, Takuji Torimura. Liver Int 2020
142
13

Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial.
Zobair M Younossi, Vlad Ratziu, Rohit Loomba, Mary Rinella, Quentin M Anstee, Zachary Goodman, Pierre Bedossa, Andreas Geier, Susanne Beckebaum, Philip N Newsome,[...]. Lancet 2019
488
11

A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis.
Philip N Newsome, Kristine Buchholtz, Kenneth Cusi, Martin Linder, Takeshi Okanoue, Vlad Ratziu, Arun J Sanyal, Anne-Sophie Sejling, Stephen A Harrison. N Engl J Med 2021
357
11

From NAFLD to MAFLD: Implications of a Premature Change in Terminology.
Zobair M Younossi, Mary E Rinella, Arun J Sanyal, Stephen A Harrison, Elizabeth M Brunt, Zachary Goodman, David E Cohen, Rohit Loomba. Hepatology 2021
141
11

The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population.
Giorgio Bedogni, Stefano Bellentani, Lucia Miglioli, Flora Masutti, Marilena Passalacqua, Anna Castiglione, Claudio Tiribelli. BMC Gastroenterol 2006
10

Comparison of MAFLD and NAFLD diagnostic criteria in real world.
Su Lin, Jiaofeng Huang, Mingfang Wang, Rahul Kumar, Yuxiu Liu, Shiying Liu, Yinlian Wu, Xiaozhong Wang, Yueyong Zhu. Liver Int 2020
199
10

Mechanisms of NAFLD development and therapeutic strategies.
Scott L Friedman, Brent A Neuschwander-Tetri, Mary Rinella, Arun J Sanyal. Nat Med 2018
10

Metabolic Dysfunction-Associated Fatty Liver Disease and Incident Cardiovascular Disease Risk: A Nationwide Cohort Study.
Hokyou Lee, Yong-Ho Lee, Seung Up Kim, Hyeon Chang Kim. Clin Gastroenterol Hepatol 2021
110
10

The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD.
Paul Angulo, Jason M Hui, Giulio Marchesini, Ellisabetta Bugianesi, Jacob George, Geoffrey C Farrell, Felicity Enders, Sushma Saksena, Alastair D Burt, John P Bida,[...]. Hepatology 2007
9

Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study.
Matthew James Armstrong, Piers Gaunt, Guruprasad P Aithal, Darren Barton, Diana Hull, Richard Parker, Jonathan M Hazlehurst, Kathy Guo, George Abouda, Mark A Aldersley,[...]. Lancet 2016
944
9

Impact of the New Definition of Metabolic Associated Fatty Liver Disease on the Epidemiology of the Disease.
Vincent Wai-Sun Wong, Grace Lai-Hung Wong, Jean Woo, Jill M Abrigo, Carmen Ka-Man Chan, Sally She-Ting Shu, Julie Ka-Yu Leung, Angel Mei-Ling Chim, Alice Pik-Shan Kong, Grace Chung-Yan Lui,[...]. Clin Gastroenterol Hepatol 2021
63
14

Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease.
Stefano Romeo, Julia Kozlitina, Chao Xing, Alexander Pertsemlidis, David Cox, Len A Pennacchio, Eric Boerwinkle, Jonathan C Cohen, Helen H Hobbs. Nat Genet 2008
9

From NAFLD to MAFLD: when pathophysiology succeeds.
Herbert Tilg, Maria Effenberger. Nat Rev Gastroenterol Hepatol 2020
96
9

Global Perspectives on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis.
Zobair Younossi, Frank Tacke, Marco Arrese, Barjesh Chander Sharma, Ibrahim Mostafa, Elisabetta Bugianesi, Vincent Wai-Sun Wong, Yusuf Yilmaz, Jacob George, Jiangao Fan,[...]. Hepatology 2019
698
8

Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis.
Eduardo Vilar-Gomez, Yadina Martinez-Perez, Luis Calzadilla-Bertot, Ana Torres-Gonzalez, Bienvenido Gra-Oramas, Licet Gonzalez-Fabian, Scott L Friedman, Moises Diago, Manuel Romero-Gomez. Gastroenterology 2015
8

Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial.
Brent A Neuschwander-Tetri, Rohit Loomba, Arun J Sanyal, Joel E Lavine, Mark L Van Natta, Manal F Abdelmalek, Naga Chalasani, Srinivasan Dasarathy, Anna Mae Diehl, Bilal Hameed,[...]. Lancet 2015
8

Asia-Pacific Working Party on Non-alcoholic Fatty Liver Disease guidelines 2017-Part 1: Definition, risk factors and assessment.
Vincent Wai-Sun Wong, Wah-Kheong Chan, Shiv Chitturi, Yogesh Chawla, Yock Young Dan, Ajay Duseja, Jiangao Fan, Khean-Lee Goh, Masahide Hamaguchi, Etsuko Hashimoto,[...]. J Gastroenterol Hepatol 2018
228
7

Redefining fatty liver disease: an international patient perspective.
Gamal Shiha, Marko Korenjak, Wayne Eskridge, Teresa Casanovas, Patricia Velez-Moller, Sari Högström, Ben Richardson, Christopher Munoz, Sólveig Sigurðardóttir, Alioune Coulibaly,[...]. Lancet Gastroenterol Hepatol 2021
87
8

What's in a name? Renaming 'NAFLD' to 'MAFLD'.
Yasser Fouad, Imam Waked, Steven Bollipo, Ahmed Gomaa, Yousef Ajlouni, Dina Attia. Liver Int 2020
138
7

Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: a meta-analysis.
Ruben Hernaez, Mariana Lazo, Susanne Bonekamp, Ihab Kamel, Frederick L Brancati, Eliseo Guallar, Jeanne M Clark. Hepatology 2011
823
7

Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies.
Siddharth Singh, Alina M Allen, Zhen Wang, Larry J Prokop, Mohammad H Murad, Rohit Loomba. Clin Gastroenterol Hepatol 2015
837
7

Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening.
Vlad Ratziu, Stephen A Harrison, Sven Francque, Pierre Bedossa, Philippe Lehert, Lawrence Serfaty, Manuel Romero-Gomez, Jérôme Boursier, Manal Abdelmalek, Steve Caldwell,[...]. Gastroenterology 2016
636
7

Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis.
Arun J Sanyal, Naga Chalasani, Kris V Kowdley, Arthur McCullough, Anna Mae Diehl, Nathan M Bass, Brent A Neuschwander-Tetri, Joel E Lavine, James Tonascia, Aynur Unalp,[...]. N Engl J Med 2010
7


NAFLD: a multisystem disease.
Christopher D Byrne, Giovanni Targher. J Hepatol 2015
7

The natural history of nonalcoholic fatty liver disease: a population-based cohort study.
Leon A Adams, James F Lymp, Jenny St Sauver, Schuyler O Sanderson, Keith D Lindor, Ariel Feldstein, Paul Angulo. Gastroenterology 2005
7

Outcomes of NAFLD and MAFLD: Results from a community-based, prospective cohort study.
Madunil Anuk Niriella, Dileepa Senajith Ediriweera, Anuradhani Kasturiratne, Shamila Thivanshi De Silva, Anuradha Supun Dassanayaka, Arjuna Priyadarshin De Silva, Norihiro Kato, Arunasalam Pathmeswaran, Ananda Rajitha Wickramasinghe, Hithanadura Janaka de Silva. PLoS One 2021
38
18

Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease.
Kerry L Donnelly, Coleman I Smith, Sarah J Schwarzenberg, Jose Jessurun, Mark D Boldt, Elizabeth J Parks. J Clin Invest 2005
7

Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease.
J Ludwig, T R Viggiano, D B McGill, B J Oh. Mayo Clin Proc 1980
7

Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030.
Chris Estes, Quentin M Anstee, Maria Teresa Arias-Loste, Heike Bantel, Stefano Bellentani, Joan Caballeria, Massimo Colombo, Antonio Craxi, Javier Crespo, Christopher P Day,[...]. J Hepatol 2018
625
7


Mechanisms and disease consequences of nonalcoholic fatty liver disease.
Rohit Loomba, Scott L Friedman, Gerald I Shulman. Cell 2021
229
7

MAFLD and risk of CKD.
Dan-Qin Sun, Yan Jin, Ting-Yao Wang, Kenneth I Zheng, Rafael S Rios, Hao-Yang Zhang, Giovanni Targher, Christopher D Byrne, Wei-Jie Yuan, Ming-Hua Zheng. Metabolism 2021
88
7

Differential Clinical Characteristics and Mortality Outcomes in Persons With NAFLD and/or MAFLD.
Vy H Nguyen, Michael H Le, Ramsey C Cheung, Mindie H Nguyen. Clin Gastroenterol Hepatol 2021
30
23

Metabolic dysfunction-associated fatty liver disease is associated with increased all-cause mortality in the United States.
Donghee Kim, Peter Konyn, Keeryth K Sandhu, Brittany B Dennis, Amanda C Cheung, Aijaz Ahmed. J Hepatol 2021
81
8

Association of MAFLD With Diabetes, Chronic Kidney Disease, and Cardiovascular Disease: A 4.6-Year Cohort Study in China.
Yebei Liang, Hongli Chen, Yuexing Liu, Xuhong Hou, Li Wei, Yuqian Bao, Chunguang Yang, Geng Zong, Jiarui Wu, Weiping Jia. J Clin Endocrinol Metab 2022
30
23

Nomenclature and definition of metabolic-associated fatty liver disease: a consensus from the Middle East and north Africa.
Gamal Shiha, Khalid Alswat, Maryam Al Khatry, Ala I Sharara, Necati Örmeci, Imam Waked, Mustapha Benazzouz, Fuad Al-Ali, Abd Elkhalek Hamed, Waseem Hamoudi,[...]. Lancet Gastroenterol Hepatol 2021
69
10

Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management.
Stuart McPherson, Tim Hardy, Elsbeth Henderson, Alastair D Burt, Christopher P Day, Quentin M Anstee. J Hepatol 2015
621
6

Fibrosis Severity as a Determinant of Cause-Specific Mortality in Patients With Advanced Nonalcoholic Fatty Liver Disease: A Multi-National Cohort Study.
Eduardo Vilar-Gomez, Luis Calzadilla-Bertot, Vincent Wai-Sun Wong, Marlen Castellanos, Rocio Aller-de la Fuente, Mayada Metwally, Mohammed Eslam, Licet Gonzalez-Fabian, María Alvarez-Quiñones Sanz, Antonio Felix Conde-Martin,[...]. Gastroenterology 2018
360
6

Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999-2019: a systematic review and meta-analysis.
Jie Li, Biyao Zou, Yee Hui Yeo, Yuemin Feng, Xiaoyu Xie, Dong Hyun Lee, Hideki Fujii, Yuankai Wu, Leslie Y Kam, Fanpu Ji,[...]. Lancet Gastroenterol Hepatol 2019
325
6

Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection.
Richard K Sterling, Eduardo Lissen, Nathan Clumeck, Ricard Sola, Mendes Cassia Correa, Julio Montaner, Mark S Sulkowski, Francesca J Torriani, Doug T Dieterich, David L Thomas,[...]. Hepatology 2006
6

Risk of severe illness from COVID-19 in patients with metabolic dysfunction-associated fatty liver disease and increased fibrosis scores.
Giovanni Targher, Alessandro Mantovani, Christopher D Byrne, Xiao-Bo Wang, Hua-Dong Yan, Qing-Feng Sun, Ke-Hua Pan, Kenneth I Zheng, Yong-Ping Chen, Mohammed Eslam,[...]. Gut 2020
110
6

Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis.
Giovanni Targher, Christopher D Byrne, Amedeo Lonardo, Giacomo Zoppini, Corrado Barbui. J Hepatol 2016
664
6


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.